Boston Scientific Return on Equity

Boston Scientific (BSX) currently reports a ROE of 14.71%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Boston Scientific's ROE history and peer comparisons.

Boston Scientific's ROE of 14.71% is lower than the Healthcare sector average of 21.67%. That is roughly 32.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Boston Scientific's current 14.71% should be judged against Healthcare norms (sector average: 21.67%) and against BSX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 14.71%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Boston Scientific, and consider following BSX for alerts when major investors trade the stock.

Boston Scientific is classified in the Healthcare sector. On ROE, it currently shows 14.71% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BSX with unrelated industries.